Patents by Inventor Matt Aaron Tschantz

Matt Aaron Tschantz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
    Publication number: 20210009567
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Application
    Filed: July 23, 2020
    Publication date: January 14, 2021
    Inventors: Todd BOSANAC, Joerg BENTZIEN, Michael Jason BURKE, Ryan Michael FRYER, Eric Thomas LARSON, Wang MAO, Bryan Patrick MCKIBBEN, Yue SHEN, Fariba SOLEYMANZADEH, Matt Aaron TSCHANTZ
  • HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
    Publication number: 20200055843
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Application
    Filed: August 29, 2019
    Publication date: February 20, 2020
    Inventors: Todd BOSANAC, Joerg BENTZIEN, Michael Jason BURKE, Ryan Michael FRYER, Eric Thomas LARSON, Wang MAO, Bryan Patrick MCKIBBEN, Yue SHEN, Fariba SOLEYMANZADEH, Matt Aaron TSCHANTZ
  • HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
    Publication number: 20190092759
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Application
    Filed: September 21, 2018
    Publication date: March 28, 2019
    Inventors: Todd BOSANAC, Joerg BENTZIEN, Michael Jason BURKE, Ryan Michael FRYER, Eric Thomas LARSON, Wang MAO, Bryan Patrick MCKIBBEN, Yue SHEN, Fariba SOLEYMANZADEH, Matt Aaron TSCHANTZ
  • HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
    Publication number: 20180222893
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Application
    Filed: April 9, 2018
    Publication date: August 9, 2018
    Inventors: Todd BOSANAC, Joerg BENTZIEN, Michael Jason BURKE, Ryan Michael FRYER, Eric Thomas LARSON, Wang MAO, Bryan Patrick MCKIBBEN, Yue SHEN, Fariba SOLEYMANZADEH, Matt Aaron TSCHANTZ
  • Heteroaromatic compounds as BTK inhibitors
    Patent number: 9975882
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: May 22, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Todd Bosanac, Joerg Bentzien, Michael Jason Burke, Ryan Michael Fryer, Eric Thomas Larson, Wang Mao, Bryan Patrick McKibben, Yue Shen, Fariba Soleymanzadeh, Matt Aaron Tschantz
  • HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
    Publication number: 20180030037
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Application
    Filed: October 12, 2017
    Publication date: February 1, 2018
    Inventors: Todd BOSANAC, Joerg BENTZIEN, Michael Jason BURKE, Ryan Michael FRYER, Eric Thomas LARSON, Wang MAO, Bryan Patrick MCKIBBEN, Yue SHEN, Fariba SOLEYMANZADEH, Matt Aaron TSCHANTZ
  • Heteroaromatic compounds as BTK inhibitors
    Patent number: 9815822
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: November 14, 2017
    Assignee: Boehringer Ingelheim Internatinal GmbH
    Inventors: Todd Bosanac, Joerg Bentzien, Michael Jason Burke, Ryan Michael Fryer, Eric Thomas Larson, Wang Mao, Bryan Patrick McKibben, Yue Shen, Fariba Soleymanzadeh, Matt Aaron Tschantz
  • HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
    Publication number: 20170174663
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Application
    Filed: December 15, 2016
    Publication date: June 22, 2017
    Inventors: Todd BOSANAC, Joerg BENTZIEN, Michael Jason BURKE, Ryan Michael FRYER, Eric Thomas LARSON, Wang MAO, Bryan Patrick MCKIBBEN, Yue SHEN, Fariba SOLEYMANZADEH, Matt Aaron TSCHANTZ
  • Fused thiazin-3-ones as KCA3.1 inhibitors
    Patent number: 9533999
    Abstract: The present invention encompasses compounds of the formulas (I) & (II), wherein the groups A, L and Ar are defined as in claim 1, which are suitable for the treatment of diseases related to KCa3.1, process of making, pharmaceutical preparations which contain compounds and their methods of use.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: January 3, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Michael J. Burke, Bryan McKibben, Matt Aaron Tschantz
  • FUSED THIAZIN-3-ONES AS KCA3.1 INHIBITORS
    Publication number: 20150232484
    Abstract: The present invention encompasses compounds of the formulas (I) & (II), wherein the groups A, L and Ar are defined as in claim 1, which are suitable for the treatment of diseases related to KCa3.1, process of making, pharmaceutical preparations which contain compounds and their methods of use.
    Type: Application
    Filed: June 12, 2013
    Publication date: August 20, 2015
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Michael J. Burke, Bryan Mckibben, Matt Aaron Tschantz
  • Derivatives of 6,7-dihydro-5H-imidazo[1,2-alpha]imidazole-3-carboxylic acid amides
    Patent number: 8552205
    Abstract: Derivatives of 6,7-dihydro-5H-imidazo[1,2-?]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.
    Type: Grant
    Filed: November 20, 2008
    Date of Patent: October 8, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Antonio Jose del Moral Barbosa, Jr., Joerg Martin Bentzien, Steven Richard Brunette, Zhidong Chen, Derek Cogan, Donghong A. Gao, Alexander Heim-Riether, Joshua Courtney Horan, Jennifer A. Kowalski, Michael David Lawlor, Rene Marc Lemieux, Weimin Liu, Bryan McKibben, Craig Andrew Miller, Neil Moss, Matt Aaron Tschantz, Zhaoming Xiong, Hui Yu, Yang Yu
  • Derivatives of 6,7-dihydro-5-imidazo[1,2-?]imidazole-3-carboxylic acid amides
    Patent number: 8481750
    Abstract: Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.
    Type: Grant
    Filed: May 28, 2010
    Date of Patent: July 9, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Jennifer A. Kowalski, Matt Aaron Tschantz
  • DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES
    Publication number: 20120178734
    Abstract: Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.
    Type: Application
    Filed: May 28, 2010
    Publication date: July 12, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Jennifer A. Kowalski, Matt Aaron Tschantz
  • DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-alpha]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES
    Publication number: 20110224188
    Abstract: Derivatives of 6,7-dihydro-5H-imidazo[1,2-?]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.
    Type: Application
    Filed: November 20, 2008
    Publication date: September 15, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Antonio Jose del Moral Barbosa, Joerg Martin Benzien, Steven Richard Brunette, Zhidong Chen, Derek Cogan, Donghong A. Gao, Alexander Heim-Riether, Joshua Courtney Horan, Jennifer A. Kowalski, Michael David Lawlor, Rene Marc Lemieux, Weimin Liu, Bryan Mckibben, Craig Andrew Miller, Neil Moss, Matt Aaron Tschantz, Zhaoming Xiong, Hui Yu, Yang Yu
  • Pyrimidine derivatives useful as inhibitors of PKC-theta
    Patent number: 7601714
    Abstract: Disclosed are novel compounds of formula (I): wherein X, Y, R1, R2 and R3 are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: July 6, 2005
    Date of Patent: October 13, 2009
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Antonio J. M. Barbosa, Jr., Steven Richard Brunette, Eugene Richard Hickey, Jin Mi Kim, Michael David Lawlor, René Marc Lemieux, Bryan McKibben, Matt Aaron Tschantz, Hui Yu
  • Substituted benzylimidazoles useful for the treatment of inflammatory diseases
    Patent number: 7572921
    Abstract: The invention comprises a class of derivatives of substituted benzylimidazoles of the formula (I) and methods for making the same. These compounds are useful for the treatment of inflammatory conditions.
    Type: Grant
    Filed: April 4, 2006
    Date of Patent: August 11, 2009
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Jin Mi Kim, Rene' Marc Lemieux, Bryan McKibben, Matt Aaron Tschantz, Hui Yu
  • Pyrimidine Derivatives Useful as Inhibitors of Pkc-Theta
    Publication number: 20080318929
    Abstract: Disclosed are novel compounds of formula (I) wherein R1, R2, R3, and R4 and A are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: December 12, 2006
    Publication date: December 25, 2008
    Inventors: Antonio J.M. Barbosa, Steven Richard Brunette, Eugene Richard Hickey, Michael David Lawlor, Matt Aaron Tschantz
  • Pyridine derivatives useful as inhibitors of PKC-theta
    Patent number: 7468382
    Abstract: Disclosed are novel compounds of formula (I): wherein R1, R2 and R3 are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: March 27, 2006
    Date of Patent: December 23, 2008
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Steven Richard Brunette, Jin Mi Kim, Rene′ Marc Lemieux, Matt Aaron Tschantz
  • Derivatives of [6,7-dihydro-5-imidazo[1,2-]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide
    Patent number: 7462637
    Abstract: Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide which exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.
    Type: Grant
    Filed: October 20, 2004
    Date of Patent: December 9, 2008
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Terence A. Kelly, Jin Mi Kim, René Marc Lemieux, Matt Aaron Tschantz
  • PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA
    Publication number: 20080287410
    Abstract: Disclosed are novel compounds of formula (I): wherein X, Y, R1, R2 and R3 are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: July 11, 2008
    Publication date: November 20, 2008
    Inventors: Antonio J.M. BARBOSA, Steven Richard BRUNETTE, Eugene Richard HICKEY, Jin Mi KIM, Michael David LAWLOR, Rene Marc LEMIEUX, Bryan MCKIBBEN, Matt Aaron TSCHANTZ, Hui YU